The home of the Audio Journal of Oncology
AUDIO JOURNAL OF ONCOLOGY—Cell Therapy Markedly Improved Outcomes After Immunotherapy in Melanoma

AUDIO JOURNAL OF ONCOLOGY—Cell Therapy Markedly Improved Outcomes After Immunotherapy in Melanoma

Play episode

Audio Journal of Oncology Podcast
Audio Journal of Oncology Podcast
AUDIO JOURNAL OF ONCOLOGY—Cell Therapy Markedly Improved Outcomes After Immunotherapy in Melanoma
Loading
/

PARIS, France—Patients who had cell therapy as second-line treatment for their advanced melanoma lived twice as long without disease progression compared with those who merely continued with pure immunotherapy. This finding came from a phase three randomized study reported at the 2022 Congress of the European Society for Medical Oncology (ESMO) by Amsterdam-based researchers, who said some of the patients may have been cured.

The second-line cell therapy consisted of re-infusion of autologous tumor infiltrating cells that had been harvested from patients own tumors and expanded ex-vivo. This followed initial immunotherapy with the checkpoint inhibitor ipilimumab.

The Audio Journal of Oncology hears from first author John B. Haanen MD PhD, Leader of Immunotherapy Research and Consultant in Medical Oncology at the Netherlands Cancer Institute in Amsterdam, in discussion with Peter Goodwin.

More from this show

Sign up for AudioMedica.com news

* = required field
Speciality